https://layoffcheck.com/companies/23andme Layoff and WARN notices reported for 23andMe. en-us https://layoffcheck.com/companies/23andme#2024-11 https://layoffcheck.com/companies/23andme#2024-11-555 Mon, 11 Nov 2024 12:00:00 GMT 23andMe cut more than 200 employees on November 11, 2024, a reduction of roughly 40% of its workforce, and simultaneously shut down its entire therapeutics division. The genetic testing company, which had seen its stock fall from a 2021 peak of over $300 per share to under $5, said the cuts would save more than $35 million annually. Clinical trials were to be wound down "as quickly as practical," and assets from the drug research programs, including cancer treatment studies, were put up for evaluation. CEO Anne Wojcicki called the actions "difficult but necessary" to put the company on "a more sustainable path" and refocus on its core consumer DNA testing and research partnerships. The restructuring carried approximately $12 million in severance and transition costs. The layoffs came weeks after the company's entire independent board had resigned in September, following Wojcicki's failed attempt to take the company private, and months after a cyberattack had exposed the genetic data of 6.9 million users. https://layoffcheck.com/companies/23andme#2023-08 https://layoffcheck.com/companies/23andme#2023-08-1487 Tue, 08 Aug 2023 12:00:00 GMT 23andMe reported a workforce reduction in SF Bay Area in August 8, 2023. https://layoffcheck.com/companies/23andme#2023-06 https://layoffcheck.com/companies/23andme#2023-06-1703 Fri, 09 Jun 2023 12:00:00 GMT 23andMe reported a workforce reduction in SF Bay Area in June 9, 2023.